Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)

NCT06295965 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT06295965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06295965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)
Lead sponsor
University of Washington
Phase
Observational
Overall status
Recruiting
Start date
January 2, 2024
Completion date
December 31, 2031
Enrollment
2,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clonal cytopenia of undetermined significance, clonal hematopoiesis, idiopathic cytopenia of undetermined significance, myeloid neoplasm post cytotoxic therapy, non-neoplastic hematopoietic and lymphoid cell disorder, ovarian carcinoma, recurrent fallopian tube carcinoma, recurrent malignant solid neoplasm, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma